# Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

> **NCT01094769** · PHASE4 · COMPLETED · sponsor: **Baker Heart and Diabetes Institute** · enrollment: 48 (estimated)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **DRUG:** Moxonidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01094769
- **Lead sponsor:** Baker Heart and Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2020-01
- **Final completion:** 2020-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01094769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01094769, "Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01094769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*